Web-Presence will introduce the HeartCheck™ device to a global network of patients and affiliate organizations
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, today announced an agency agreement with Arrhythmia Alliance based out of the United Kingdom. The Arrhythmia Alliance, operated under The Heart Rhythm Charity®, is a global coalition of independent charities, patient groups, patients, care givers, medical groups and allied professionals that work together under the Arrhythmia Alliance umbrella to promote timely and effective diagnosis and treatment of arrhythmias.
The agreement designates the Arrhythmia Alliance website as an authorized source for the purchase of the Company’s HeartCheck™ PEN. As a patient advocacy group and umbrella organization, the Arrhythmia Alliance promotion will reach thousands of registered people living with or caring for persons with arrhythmias such as atrial fibrillation (“AF”). With over 25,000 Arrhythmia Alliance members with AF, this will mark the largest focused introduction of the HeartCheck™ PEN and SMART Monitoring ECG service to the consumer arrhythmia market.
“The launch of this latest phase of our HeartCheck™ advertising campaign represents a significant opportunity for the introduction of the HeartCheck™ PEN into a large market of consumers who are specifically informed on the importance of managing arrhythmias and the importance of following the progression and/or treatment of AF in an effort to prevent stroke. This relationship meets our mutual objectives to provide an easy to use and validated arrhythmia monitoring solution to those people interested in the preservation of their health as well as those at risk for developing arrhythmia-based cardiac disease due to underlying conditions such as hypertension, diabetes, older age, familial histories and taking high risk medications,” said Etienne Grima, Chief Executive Officer for CardioComm Solutions.
Consumers purchasing the HeartCheck™ PEN ECG will have access to CardioComm Solutions’ SMART Monitoring ECG service, a free first ECG interpretation and the free GEMS™ Home software. The HeartCheck™ PEN is the only consumer device permitted by the US Food and Drug Administration (FDA) and Health Canada to display a person’s actual ECG tracing as an over-the-counter (OTC) consumer product. The HeartCheck™ PEN is also CE marked, allowing it to be sold within the European Union and other international locations that recognize FDA, CE and ISO regulatory compliance. The SMART Monitoring ECG service is capable of accepting ECGs from HeartCheck™ devices anywhere in the world with internet access and can return an interpreted ECG report within an average time of 30 minutes, 24/7. The device is also capable of storing and replaying up to 20 ECG recordings.
“We have come to know the HeartCheck™ PEN and CardioComm Solutions through their presence at international medical conferences and their participation in research projects. Providing individuals with an option for self-monitoring of their cardiac rhythm with added ability to capture and identify what arrhythmia may exist is important enough to have devices like the HeartCheck™ PEN featured as a life saving device on our membership website http://www.heartrhythmcharity.org.uk,” reported Trudie Lobban, Founder & Trustee of the Arrhythmia Alliance.
“We have established several advocacy-based relationships and intend to continue to expand awareness of the availability of our HeartCheck™ solutions and SMART Monitoring services through collaboration with recognized organizations such as the Arrhythmia Alliance. With material efforts invested in AF detection and awareness, CardioComm Solutions will now expand its program into the monitoring of arrhythmias in patients with congestive heart failure, and specifically, widening of the QRS complex as a risk factor for sudden cardiac death. It is exciting to be associated with an organization that can make such an impact on the health of so many,” closed Simi Grosman, member of the CardioComm Solutions Board of Directors.
